Seliciclib was more potent against CDKs 2, 5, and 7 (IC50 = 100, 160, and 490 nM, respectively) than CDK9 (230), and demonstrated anticancer activities in numerous preclinical cancer models by inducing cell cycle arrest and apoptosis (231, 232). This evidence concerns the gene CDK9 and cancer.